Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Acquired Resistance to Immune Checkpoint Inhibitors
Adam J. Schoenfeld, Matthew D. Hellmann
Cancer Cell (2020) Vol. 37, Iss. 4, pp. 443-455
Open Access | Times Cited: 665

Showing 1-25 of 665 citing articles:

CD8+ T cell differentiation and dysfunction in cancer
Mary Philip, Andrea Schietinger
Nature reviews. Immunology (2021) Vol. 22, Iss. 4, pp. 209-223
Open Access | Times Cited: 686
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
Yves Fradet, Joaquim Bellmunt, David J. Vaughn, et al.
Annals of Oncology (2019) Vol. 30, Iss. 6, pp. 970-976
Open Access | Times Cited: 399
Pyroptosis: a new paradigm of cell death for fighting against cancer
Yixin Tan, Quanzhu Chen, Xiaoling Li, et al.
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 358
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
Scott Antonia, Hossein Borghaei, Suresh S. Ramalingam, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 10, pp. 1395-1408
Open Access | Times Cited: 301
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Meng‐Ling Wu, Qianrui Huang, Yao Xie, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 299
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial
Ben Creelan, Chao Wang, Jamie K. Teer, et al.
Nature Medicine (2021) Vol. 27, Iss. 8, pp. 1410-1418
Open Access | Times Cited: 293
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Adel Naimi, Rebar N. Mohammed, Ahmed Raji, et al.
Cell Communication and Signaling (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 286
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
Matthew D. Vesely, Tianxiang Zhang, Lieping Chen
Annual Review of Immunology (2022) Vol. 40, Iss. 1, pp. 45-74
Closed Access | Times Cited: 270
Tumor Immune Microenvironment during Epithelial–Mesenchymal Transition
Mana Taki, Kaoru Abiko, Masayo Ukita, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 17, pp. 4669-4679
Open Access | Times Cited: 235
Signal pathways of melanoma and targeted therapy
Weinan Guo, Huina Wang, Chunying Li
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 228
Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook
Lena Horvath, Bernard Thienpont, Liyun Zhao, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 199
Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies
Mihaela Aldea, Fabrice André, Aurélien Marabelle, et al.
Cancer Discovery (2021) Vol. 11, Iss. 4, pp. 874-899
Open Access | Times Cited: 197
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies
Antonio Passaro, Julie R. Brahmer, Scott Antonia, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 6, pp. 598-610
Closed Access | Times Cited: 188
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Somayeh Vafaei, Angelina Olegovna Zekiy, Ramadhan Ado Khanamir, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 176
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
Yuchen Wang, Hao Zhang, Chao Liu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 176
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial
Jonathan D. Schoenfeld, Anita Giobbie‐Hurder, Srinika Ranasinghe, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 2, pp. 279-291
Open Access | Times Cited: 174
The cutting-edge progress of immune-checkpoint blockade in lung cancer
Fei Zhou, Meng Qiao, Caicun Zhou
Cellular and Molecular Immunology (2020) Vol. 18, Iss. 2, pp. 279-293
Open Access | Times Cited: 158
Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification
Bowen Li, Jingwen Jiang, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100720-100720
Closed Access | Times Cited: 141
Myeloid-derived suppressor cells in cancer and cancer therapy
Samantha Lasser, Feyza Gül Özbay Kurt, Ihor Arkhypov, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 2, pp. 147-164
Closed Access | Times Cited: 136
Advances in immunotherapy for triple-negative breast cancer
Yang Liu, Yueting Hu, Jinqi Xue, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 123
Immune Checkpoint Inhibitors in Human Glioma Microenvironment
Amina Ghouzlani, Sarah Kandoussi, Mariam Tall, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 120
Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired
Hany E. Marei, Anwarul Hasan, Giacomo Pozzoli, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 117
Tumor Associated Macrophages: Origin, Recruitment, Phenotypic Diversity, and Targeting
Tetiana Hourani, James A. Holden, Wenyi Li, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 116
Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
James J. Harding, Víctor Moreno, Yung‐Jue Bang, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 8, pp. 2168-2178
Open Access | Times Cited: 115
Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer
J. Li, Jiao Liu, Zhuan Zhou, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 720
Closed Access | Times Cited: 113
Page 1 - Next Page

Scroll to top